EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in Humans

Ephrin receptors constitute a large family of receptor tyrosine kinases in mammals that through interaction with cell surface-anchored ephrin ligands regulate multiple different cellular responses in numerous cell types and tissues. In the cardiovascular system, studies performed in vitro and in viv...

Full description

Bibliographic Details
Main Authors: Di Chen, Martijn A. Van der Ent, Nathaniel L. Lartey, Philip D. King
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/16/2/165
_version_ 1827755980556861440
author Di Chen
Martijn A. Van der Ent
Nathaniel L. Lartey
Philip D. King
author_facet Di Chen
Martijn A. Van der Ent
Nathaniel L. Lartey
Philip D. King
author_sort Di Chen
collection DOAJ
description Ephrin receptors constitute a large family of receptor tyrosine kinases in mammals that through interaction with cell surface-anchored ephrin ligands regulate multiple different cellular responses in numerous cell types and tissues. In the cardiovascular system, studies performed in vitro and in vivo have pointed to a critical role for Ephrin receptor B4 (EPHB4) as a regulator of blood and lymphatic vascular development and function. However, in this role, EPHB4 appears to act not as a classical growth factor receptor but instead functions to dampen the activation of the Ras-mitogen activated protein signaling (MAPK) pathway induced by other growth factor receptors in endothelial cells (EC). To inhibit the Ras-MAPK pathway, EPHB4 interacts functionally with Ras p21 protein activator 1 (RASA1) also known as p120 Ras GTPase-activating protein. Here, we review the evidence for an inhibitory role for an EPHB4–RASA1 interface in EC. We further discuss the mechanisms by which loss of EPHB4–RASA1 signaling in EC leads to blood and lymphatic vascular abnormalities in mice and the implications of these findings for an understanding of the pathogenesis of vascular anomalies in humans caused by mutations in <i>EPHB4</i> and <i>RASA1</i> genes. Last, we provide insights into possible means of drug therapy for EPHB4- and RASA1-related vascular anomalies.
first_indexed 2024-03-11T08:17:44Z
format Article
id doaj.art-3dbfde3b3fd443bfbb2003f52ec33eb5
institution Directory Open Access Journal
issn 1424-8247
language English
last_indexed 2024-03-11T08:17:44Z
publishDate 2023-01-01
publisher MDPI AG
record_format Article
series Pharmaceuticals
spelling doaj.art-3dbfde3b3fd443bfbb2003f52ec33eb52023-11-16T22:35:55ZengMDPI AGPharmaceuticals1424-82472023-01-0116216510.3390/ph16020165EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in HumansDi Chen0Martijn A. Van der Ent1Nathaniel L. Lartey2Philip D. King3Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USADepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USADepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USADepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USAEphrin receptors constitute a large family of receptor tyrosine kinases in mammals that through interaction with cell surface-anchored ephrin ligands regulate multiple different cellular responses in numerous cell types and tissues. In the cardiovascular system, studies performed in vitro and in vivo have pointed to a critical role for Ephrin receptor B4 (EPHB4) as a regulator of blood and lymphatic vascular development and function. However, in this role, EPHB4 appears to act not as a classical growth factor receptor but instead functions to dampen the activation of the Ras-mitogen activated protein signaling (MAPK) pathway induced by other growth factor receptors in endothelial cells (EC). To inhibit the Ras-MAPK pathway, EPHB4 interacts functionally with Ras p21 protein activator 1 (RASA1) also known as p120 Ras GTPase-activating protein. Here, we review the evidence for an inhibitory role for an EPHB4–RASA1 interface in EC. We further discuss the mechanisms by which loss of EPHB4–RASA1 signaling in EC leads to blood and lymphatic vascular abnormalities in mice and the implications of these findings for an understanding of the pathogenesis of vascular anomalies in humans caused by mutations in <i>EPHB4</i> and <i>RASA1</i> genes. Last, we provide insights into possible means of drug therapy for EPHB4- and RASA1-related vascular anomalies.https://www.mdpi.com/1424-8247/16/2/165Ephrin receptor B4RASA1Ras-MAPK pathwaycapillary malformation arteriovenous malformationlymphatic malformationangiogenesis
spellingShingle Di Chen
Martijn A. Van der Ent
Nathaniel L. Lartey
Philip D. King
EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in Humans
Pharmaceuticals
Ephrin receptor B4
RASA1
Ras-MAPK pathway
capillary malformation arteriovenous malformation
lymphatic malformation
angiogenesis
title EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in Humans
title_full EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in Humans
title_fullStr EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in Humans
title_full_unstemmed EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in Humans
title_short EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in Humans
title_sort ephb4 rasa1 mediated negative regulation of ras mapk signaling in the vasculature implications for the treatment of ephb4 and rasa1 related vascular anomalies in humans
topic Ephrin receptor B4
RASA1
Ras-MAPK pathway
capillary malformation arteriovenous malformation
lymphatic malformation
angiogenesis
url https://www.mdpi.com/1424-8247/16/2/165
work_keys_str_mv AT dichen ephb4rasa1mediatednegativeregulationofrasmapksignalinginthevasculatureimplicationsforthetreatmentofephb4andrasa1relatedvascularanomaliesinhumans
AT martijnavanderent ephb4rasa1mediatednegativeregulationofrasmapksignalinginthevasculatureimplicationsforthetreatmentofephb4andrasa1relatedvascularanomaliesinhumans
AT nathanielllartey ephb4rasa1mediatednegativeregulationofrasmapksignalinginthevasculatureimplicationsforthetreatmentofephb4andrasa1relatedvascularanomaliesinhumans
AT philipdking ephb4rasa1mediatednegativeregulationofrasmapksignalinginthevasculatureimplicationsforthetreatmentofephb4andrasa1relatedvascularanomaliesinhumans